Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”

Detalles Bibliográficos
Autores principales: Hughes, Derralynn A., Deegan, Patrick, Giraldo, Pilar, Göker-Alpan, Özlem, Lau, Heather, Lukina, Elena, Revel-Vilk, Shoshana, Scarpa, Maurizio, Botha, Jaco, Gadir, Noga, Zimran, Ari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Reply
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299381/
https://www.ncbi.nlm.nih.gov/pubmed/37373710
http://dx.doi.org/10.3390/jcm12124017
_version_ 1785064350078205952
author Hughes, Derralynn A.
Deegan, Patrick
Giraldo, Pilar
Göker-Alpan, Özlem
Lau, Heather
Lukina, Elena
Revel-Vilk, Shoshana
Scarpa, Maurizio
Botha, Jaco
Gadir, Noga
Zimran, Ari
author_facet Hughes, Derralynn A.
Deegan, Patrick
Giraldo, Pilar
Göker-Alpan, Özlem
Lau, Heather
Lukina, Elena
Revel-Vilk, Shoshana
Scarpa, Maurizio
Botha, Jaco
Gadir, Noga
Zimran, Ari
author_sort Hughes, Derralynn A.
collection PubMed
description
format Online
Article
Text
id pubmed-10299381
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102993812023-06-28 Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158” Hughes, Derralynn A. Deegan, Patrick Giraldo, Pilar Göker-Alpan, Özlem Lau, Heather Lukina, Elena Revel-Vilk, Shoshana Scarpa, Maurizio Botha, Jaco Gadir, Noga Zimran, Ari J Clin Med Reply MDPI 2023-06-13 /pmc/articles/PMC10299381/ /pubmed/37373710 http://dx.doi.org/10.3390/jcm12124017 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Reply
Hughes, Derralynn A.
Deegan, Patrick
Giraldo, Pilar
Göker-Alpan, Özlem
Lau, Heather
Lukina, Elena
Revel-Vilk, Shoshana
Scarpa, Maurizio
Botha, Jaco
Gadir, Noga
Zimran, Ari
Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”
title Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”
title_full Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”
title_fullStr Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”
title_full_unstemmed Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”
title_short Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”
title_sort reply to mistry et al. the two substrate reduction therapies for type 1 gaucher disease are not equivalent. comment on “hughes et al. switching between enzyme replacement therapies and substrate reduction therapies in patients with gaucher disease: data from the gaucher outcome survey (gos). j. clin. med. 2022, 11, 5158”
topic Reply
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299381/
https://www.ncbi.nlm.nih.gov/pubmed/37373710
http://dx.doi.org/10.3390/jcm12124017
work_keys_str_mv AT hughesderralynna replytomistryetalthetwosubstratereductiontherapiesfortype1gaucherdiseasearenotequivalentcommentonhughesetalswitchingbetweenenzymereplacementtherapiesandsubstratereductiontherapiesinpatientswithgaucherdiseasedatafromthegaucheroutcomesurveygosjclinmed202211
AT deeganpatrick replytomistryetalthetwosubstratereductiontherapiesfortype1gaucherdiseasearenotequivalentcommentonhughesetalswitchingbetweenenzymereplacementtherapiesandsubstratereductiontherapiesinpatientswithgaucherdiseasedatafromthegaucheroutcomesurveygosjclinmed202211
AT giraldopilar replytomistryetalthetwosubstratereductiontherapiesfortype1gaucherdiseasearenotequivalentcommentonhughesetalswitchingbetweenenzymereplacementtherapiesandsubstratereductiontherapiesinpatientswithgaucherdiseasedatafromthegaucheroutcomesurveygosjclinmed202211
AT gokeralpanozlem replytomistryetalthetwosubstratereductiontherapiesfortype1gaucherdiseasearenotequivalentcommentonhughesetalswitchingbetweenenzymereplacementtherapiesandsubstratereductiontherapiesinpatientswithgaucherdiseasedatafromthegaucheroutcomesurveygosjclinmed202211
AT lauheather replytomistryetalthetwosubstratereductiontherapiesfortype1gaucherdiseasearenotequivalentcommentonhughesetalswitchingbetweenenzymereplacementtherapiesandsubstratereductiontherapiesinpatientswithgaucherdiseasedatafromthegaucheroutcomesurveygosjclinmed202211
AT lukinaelena replytomistryetalthetwosubstratereductiontherapiesfortype1gaucherdiseasearenotequivalentcommentonhughesetalswitchingbetweenenzymereplacementtherapiesandsubstratereductiontherapiesinpatientswithgaucherdiseasedatafromthegaucheroutcomesurveygosjclinmed202211
AT revelvilkshoshana replytomistryetalthetwosubstratereductiontherapiesfortype1gaucherdiseasearenotequivalentcommentonhughesetalswitchingbetweenenzymereplacementtherapiesandsubstratereductiontherapiesinpatientswithgaucherdiseasedatafromthegaucheroutcomesurveygosjclinmed202211
AT scarpamaurizio replytomistryetalthetwosubstratereductiontherapiesfortype1gaucherdiseasearenotequivalentcommentonhughesetalswitchingbetweenenzymereplacementtherapiesandsubstratereductiontherapiesinpatientswithgaucherdiseasedatafromthegaucheroutcomesurveygosjclinmed202211
AT bothajaco replytomistryetalthetwosubstratereductiontherapiesfortype1gaucherdiseasearenotequivalentcommentonhughesetalswitchingbetweenenzymereplacementtherapiesandsubstratereductiontherapiesinpatientswithgaucherdiseasedatafromthegaucheroutcomesurveygosjclinmed202211
AT gadirnoga replytomistryetalthetwosubstratereductiontherapiesfortype1gaucherdiseasearenotequivalentcommentonhughesetalswitchingbetweenenzymereplacementtherapiesandsubstratereductiontherapiesinpatientswithgaucherdiseasedatafromthegaucheroutcomesurveygosjclinmed202211
AT zimranari replytomistryetalthetwosubstratereductiontherapiesfortype1gaucherdiseasearenotequivalentcommentonhughesetalswitchingbetweenenzymereplacementtherapiesandsubstratereductiontherapiesinpatientswithgaucherdiseasedatafromthegaucheroutcomesurveygosjclinmed202211

Ejemplares similares